结核分枝杆菌(Mtb)每年导致近200万人死亡。BCG是当前唯一使用的结核病疫苗,能够诱导不恒定的保护力,不能防止潜伏性结核病的复活。因此,急切需要有效的疫苗来补充BCG。由于在细菌的繁殖阶段与休眠阶段结核分枝杆菌的蛋白质组在性质和数量上不同,所以改良的结核病疫苗应该能够诱导产生对感染各个阶段表达的结核分枝杆菌抗原的免疫应答。因此,这种“复合期”疫苗应该由结核分枝杆菌感染不同阶段表达的(免疫决定簇)抗原组成。作为一个概念性多级疫苗,我们通过融合五种HLA-DR3限制性T细胞表位构建了一个多表位肽(polyepitope),这些限制性表位来源于不同 Mycobacterium tuberculosis (Mtb) causes nearly 2 million deaths each year. BCG is the only TB vaccine currently in use that induces unsustainable protection and does not prevent the resurgence of latent tuberculosis. Therefore, an urgent need for effective vaccines to supplement BCG. Due to the different nature and quantity of the M. tuberculosis proteome between the vegetative and dormant stages of bacteria, the modified tuberculosis vaccine should be able to induce an immune response to M. tuberculosis antigens expressed at all stages of infection. Therefore, this “composite phase” vaccine should consist of (immune determinant) antigens expressed at different stages of Mycobacterium tuberculosis infection. As a conceptual multistage vaccine, we constructed a polyepitope by fusion of five HLA-DR3 restricted T cell epitopes derived from different